AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15269144
Drug: BEC2 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BEC2 vaccine
Trial: 7962344
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg 17 beta‐estradiol combined with 2.5 mg dydrogesterone
Trial: 7962344
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg 17 beta‐estradiol combined with 5 mg dydrogesterone
Trial: 7962344
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg 17 beta‐estradiol combined with 10 mg dydrogesterone
Trial: 7962344
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg 17 beta‐estradiol combined with 15 mg dydrogesterone
Trial: 7962344
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg 17 beta‐estradiol combined with all doses of dydrogesterone
Trial: 28129748
Drug: Faster rate
RxNorm normalized name: diphenhydramine
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Faster rate of increase in milk feeds (30 ml/kg/day)
Trial: 28129748
Drug: Slower rate
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slower rate of increase in milk feeds (18 ml/kg/day)
Trial: 25930719
Drug: Upfront zoledronic
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Upfront zoledronic acid (ZA) 4 mg IV every 6 months
Trial: 25930719
Drug: Delayed zoledronic
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Delayed zoledronic acid (ZA) 4 mg IV every 6 months
Trial: 22268726
Drug: Control (contralateral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (contralateral arm without treatment)
Trial: 14520284
Drug: 0.25 mg
RxNorm normalized name: biotin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg of flunitrazepam (F0.25 group)
Trial: 14520284
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg of flunitrazepam (F0.5 group)
Trial: 11031393
Drug: Valacyclovir hydrochloride
RxNorm normalized name: Valacyclovir Hydrochloride
DrugBank: Valaciclovir (DB00577)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valacyclovir hydrochloride (1 g 3 times daily) for 7 days
Trial: 11031393
Drug: Famciclovir (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famciclovir (500 mg 3 times daily) for 7 days
Trial: 31288820
Drug: liraglutide (1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: liraglutide (1.8 mg/day)
Trial: 24783469
Drug: Continuous positive
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous positive airway pressure therapy (CPAP) for 24 weeks
Trial: 22722504
Drug: ziprasidone 40
RxNorm normalized name: ziprasidone 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ziprasidone 40 to 80 mg/d
Trial: 22722504
Drug: ziprasidone 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ziprasidone 120 to 160 mg/d
Trial: 22722504
Drug: ziprasidone 40
RxNorm normalized name: ziprasidone 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ziprasidone 40 to 160 mg/d
Trial: 12053117
Drug: Observed Tasks
RxNorm normalized name: MASK
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Observed Tasks of Daily Living
Trial: 9469359
Drug: BEP/EP chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BEP/EP chemotherapy regimen (bleomycin, etoposide, and cisplatin)
Trial: 9469359
Drug: BOP/VIP-B chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BOP/VIP-B chemotherapy regimen (bleomycin, vincristine, cisplatin / etoposide, ifosfamide, cisplatin, and bleomycin)
Trial: 7665441
Drug: Methylphenidate (MPH),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (MPH), 10 mg single dose
Trial: 778483
Drug: Small doses
RxNorm normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small doses of s.c. heparin
Trial: 28224289
Drug: Frontalis suspension
RxNorm normalized name: Bos taurus frontal lobe preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frontalis suspension using Gore-Tex through a skin crease incision (group I)
Trial: 28224289
Drug: Frontalis suspension
RxNorm normalized name: Bos taurus frontal lobe preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frontalis suspension using Gore-Tex through supraciliary incisions (group II)
Trial: 25886787
Drug: 7-Valent Pneumococcal
RxNorm normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-Valent Pneumococcal Conjugate Vaccine
Trial: 24002213
Drug: CB formulation
RxNorm normalized name: BroveX CB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CB formulation (Curcuma longa and Boswellia serrata extracts) 500 mg twice a day
Trial: 21385602
Drug: Citalopram (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (20 mg in 12 h)
Trial: 18823361
Drug: Fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination of acetylsalicylic acid + paracetamol + caffeine
Trial: 19472440
Drug: Pain reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pain reduction by 50% within 1 hour after drug intake
Trial: 14513922
Drug: 52 g
RxNorm normalized name: Konsyl 0.52 GM Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 52 g tryptophan depleting amino-acid drink
Trial: 11071421
Drug: ECHO36 (lemon-lime
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ECHO36 (lemon-lime ECHO with 36 mEq/L NaCl)
Trial: 11071421
Drug: ECHO18 (lemon-lime
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ECHO18 (lemon-lime ECHO with 18 mEq/L NaCl)
Trial: 26474864
Drug: Inhaled Fluticasone
RxNorm normalized name: fluticasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Fluticasone Furoate (FF)
Trial: 26474864
Drug: Inhaled Vilanterol
RxNorm normalized name: fluticasone / vilanterol Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Vilanterol (VI)
Trial: 26474864
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of FF and VI (FF/VI)
Trial: 24584918
Drug: Certolizumab pegol
RxNorm normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Certolizumab pegol (CZP) 400 mg (loading dose)
Trial: 18295212
Drug: Misoprostol (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misoprostol (800 microg) administered vaginally
Trial: 17301564
Drug: Intermittent antiretroviral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent antiretroviral therapy (8-week off, 8-week on regimen)
Trial: 17301564
Drug: Intermittent antiretroviral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent antiretroviral therapy
Trial: 319117
Drug: Flurbiprofen (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen (120 mg daily for six weeks)
Trial: 319117
Drug: Ibuprofen (2400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (2400 mg daily for six weeks)
Trial: 31515173
Drug: Patches plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patches plus nicotine e‐cigarette
Trial: 31515173
Drug: Patches plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patches plus nicotine‐free e‐cigarette
Trial: 31515173
Drug: Patches only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patches only
Trial: 28103052
Drug: Micronutrients +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronutrients + medication
Trial: 28103052
Drug: Medication only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication only (Control)
Trial: 21332679
Drug: Spinal anesthesia
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal anesthesia with intrathecal morphine
Trial: 9163639
Drug: CDP840 (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDP840 (15 mg b.i.d. for 9.5 days)
Trial: 9163639
Drug: CDP840 (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDP840 (15 and 30 mg single dose)
Trial: 30390148
Drug: Feedback Informed
RxNorm normalized name: INFORMATION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Feedback Informed Treatment (FIT)
Trial: 22155477
Drug: Dopaminergic medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopaminergic medication ON
Trial: 22155477
Drug: No dopaminergic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No dopaminergic medication OFF
Trial: 17215845
Drug: Grapefruit juice
RxNorm normalized name: grapefruit juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grapefruit juice consumption (concomitantly or 2 hours before fexofenadine administration)
Trial: 15164249
Drug: Oral sodium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral sodium phosphate with E-Lyte supplements (Group 1)
Trial: 15164249
Drug: Oral sodium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral sodium phosphate without E-Lyte supplements (Group 2)
Trial: 8777618
Drug: Pentoxifylline (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (1.2 g daily, divided into three doses for 2 months)
Trial: 6596060
Drug: Intravenous streptokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous streptokinase therapy (1 million IU over 20 minutes)
Trial: 30711868
Drug: Treatment-as-usual (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-as-usual (n = 27)
Trial: 29479906
Drug: Bevacizumab treatment
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab treatment in patients with exudative ARMD and POAG
Trial: 29479906
Drug: Bevacizumab treatment
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab treatment in patients with DME and POAG
Trial: 16885205
Drug: Cognitive remediation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive remediation therapy
Trial: 19258303
Drug: Motivational orientation
RxNorm normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational orientation intervention combined with Parent-Child Interaction Therapy (PCIT)
Trial: 11087700
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (high response)
Trial: 11087700
Drug: Sulfasalazine treatment
RxNorm normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sulfasalazine treatment (moderate response)
Trial: 9305476
Drug: Enema (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enema (100 mL suspension, 1 g mesalazine)
Trial: 9305476
Drug: Rectal foam
RxNorm normalized name: Rectal Foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal foam (1 g mesalazine in 5 mL concentrate, expanding to 40 mL on actuation)
Trial: 9305476
Drug: Suppository (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suppository (1 g mesalazine)
Trial: 3512970
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy (cisdiamminedichloro-platinum plus methotrexate)
Trial: 27511847
Drug: TARGIT‐IORT (single-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TARGIT‐IORT (single-dose intraoperative radiation therapy)
Trial: 27511847
Drug: EBRT (external
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EBRT (external beam radiation therapy)
Trial: 23284643
Drug: Umeclidinium (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Umeclidinium (500 µg) and vilanterol (50 µg) combination
Trial: 23284643
Drug: Umeclidinium (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Umeclidinium (500 µg) alone
Trial: 23284643
Drug: Vilanterol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vilanterol (50 µg) alone
Trial: 20192619
Drug: 20% lignocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% lignocaine patch
Trial: 18184544
Drug: Sijunzi Decoction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sijunzi Decoction (100 ml) administered via nasogastric tube from the second postoperation day to the 9th postoperation day, along with isocaloric and isonitrogonous enteral diet for 8 days
Trial: 18184544
Drug: Isocaloric and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isocaloric and isonitrogonous parenteral diet for 9 days
Trial: 8136110
Drug: Quinapril (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinapril (mean dose 32 mg/24 h)
Trial: 8136110
Drug: Captopril (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (mean dose 132 mg/24 h)
Trial: 2199681
Drug: Tamoxifen (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (10 mg twice a day)
Trial: 27768831
Drug: Denosumab (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denosumab (60 mg subcutaneous once)
Trial: 27768831
Drug: Alendronate (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate (70 mg oral weekly for 6 months)
Trial: 23850898
Drug: 200 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 μg misoprostol vaginally at 6 hours before outpatient hysteroscopy and placebo tablets rectally at 60 minutes before the procedure.
Trial: 23850898
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg diclofenac sodium rectally at 60 minutes before the procedure and placebo tablets rectally at 6 hours before outpatient hysteroscopy.
Trial: 23850898
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets vaginally at 6 hours before outpatient hysteroscopy and placebo tablets rectally at 45 to 60 minutes before the procedure.
Trial: 21788632
Drug: Maximal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maximal treatment group (mobile and web-based self-management patient coaching system)
Trial: 21788632
Drug: Maximal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maximal treatment group
Trial: 21788632
Drug: Maximal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maximal treatment group and Usual care
Trial: 17013438
Drug: 6-methylprednisolone (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-methylprednisolone (20 mg)
Trial: 15287932
Drug: Acarbose 100
RxNorm normalized name: acarbose 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acarbose 100 mg (one-dose)
Trial: 15287932
Drug: Acarbose 300
RxNorm normalized name: Acarbose
DrugBank: Acarbose (DB00284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acarbose 300 mg/day for 8 weeks
Trial: 15287932
Drug: Acarbose (one-dose)
RxNorm normalized name: Acarbose
DrugBank: Acarbose (DB00284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acarbose (one-dose)
Trial: 8612858
Drug: Intranasal buserelin
RxNorm normalized name: buserelin
DrugBank: Buserelin (DB06719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal buserelin acetate started in the midluteal phase
Trial: 8612858
Drug: Intranasal buserelin
RxNorm normalized name: buserelin
DrugBank: Buserelin (DB06719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal buserelin acetate started in the early follicular phase
Trial: 1611136
Drug: ponalrestat (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ponalrestat (600 mg daily)
Trial: 6360414
Drug: Cholestyramine (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholestyramine (6 g four times daily)
Trial: 16820546
Drug: Varenicline (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline (1 mg twice per day)
Trial: 28628768
Drug: Internet delivered
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet delivered Cognitive Behavior Therapy (ICBT) as an add‐on to usual care
Trial: 28628768
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (TAU) provided at their antenatal clinic
Trial: 25740744
Drug: DAG oil
RxNorm normalized name: Daglutril
DrugBank: Daglutril (DB05796)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAG oil (25 mL/d for 120 days)
Trial: 25740744
Drug: TAG oil
RxNorm normalized name: ProVent SKIN TAG OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAG oil (25 mL/d for 120 days)
Trial: 23465817
Drug: Progesterone vaginal
RxNorm normalized name: progesterone Vaginal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progesterone vaginal gel (VG)
Trial: 18663631
Drug: Estrogen and
RxNorm normalized name: Conjugated estrogen and norgestrel only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen and estrogen/progestin hormone therapies (HT)
Trial: 18663631
Drug: Timing hypothesis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timing hypothesis for hormone therapy
Trial: 14689344
Drug: Mupirocin therapy
RxNorm normalized name: Mupirocin
DrugBank: Mupirocin (DB00410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mupirocin therapy
Trial: 14689344
Drug: Placebo or
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo or no therapy
Trial: 1793154
Drug: High-dose cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cyclophosphamide (CPM) and high-dose methotrexate (MTX) with coordinated intrathecal therapy (TIT)
Trial: 6342785
Drug: Cyclacillin, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclacillin, administered three times a day for ten days
Trial: 6342785
Drug: Amoxicillin, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin, administered similarly
Trial: 29024579
Drug: Droxidopa 600
RxNorm normalized name: Droxidopa
DrugBank: Droxidopa (DB06262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Droxidopa 600 mg
Trial: 29024579
Drug: Droxidopa 2000
RxNorm normalized name: Droxidopa
DrugBank: Droxidopa (DB06262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Droxidopa 2000 mg
Trial: 12942493
Drug: Aspirin 150
RxNorm normalized name: aspirin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 150 mg per day
Trial: 1498266
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg diclofenac hydrogel bead (HGB) capsule after a standardized breakfast
Trial: 1498266
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg diclofenac hydrogel bead (HGB) capsule under fasted conditions
Trial: 26116561
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) group program
Trial: 20051618
Drug: Baseline treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline treatment programs (Control)
Trial: 11558858
Drug: Losartan monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan monotherapy (50 to 150 mg)
Trial: 11558858
Drug: Losartan/HCTZ (50/0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan/HCTZ (50/0 to 50/12.5 to 100/25 mg)
Trial: 9755543
Drug: salmeterol 50
RxNorm normalized name: FLUTICAS 100/SALMETEROL 50 INHL DISK 14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: salmeterol 50 mg twice a day
Trial: 9755543
Drug: salbutamol 200
RxNorm normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: salbutamol 200 mg four times a day
Trial: 31485804
Drug: Betaine hydrochloride
RxNorm normalized name: Betaine Hydrochloride
DrugBank: Betaine (DB06756)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betaine hydrochloride (BHCl) 4500 mg
Trial: 23801579
Drug: Teplizumab (14-day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teplizumab (14-day full-dose)
Trial: 19336502
Drug: Clopidogrel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (75 mg) added to aspirin
Trial: 10873076
Drug: Idoxifene 40
RxNorm normalized name: Idoxene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idoxifene 40 mg/day for 14-21 days
Trial: 8296487
Drug: Thymostimulin treatment
RxNorm normalized name: thymostimulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymostimulin treatment (6 subjects)
Trial: 3113973
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg X kg‐1 once daily for 3 days
Trial: 3113973
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg X kg‐1 thrice daily for one day
Trial: 3113973
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg X kg‐1 thrice daily for one day
Trial: 29445116
Drug: Traditional ophthalmic
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional ophthalmic microscope (TM) during 25-gauge pars plana vitrectomy (PPV)
Trial: 20868279
Drug: Full-dose nevirapine
RxNorm normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Full-dose nevirapine (FD)